https://www.selleckchem.com/pr....oducts/tinengotinib.
Based on these simulations we recommend point estimation using the proposed LSNT calculation and confidence interval estimation via the FRWB approach. We also provide a Shiny app that facilitates an automated implementation of the methodology.The optimal management of advanced non-small cell lung cancer (NSCLC) with noncanonical epidermal growth factor receptor (EGFR) mutations (i.e., exon 19 deletion and exon 21 L858R) is constrained by the heterogeneous behavior of individual uncommon mutations and limited prospective clinical da
Curtir
Comentario
Compartilhar
